HP
EVGN icon

Harvey Partners’s Evogene EVGN Stock Holding History

Harvey Partners’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,000
Closed -$790K – 50
2014
Q3 		$790K Hold
6,000
– – 0.46% 42
2014
Q2 		$983K Hold
6,000
– – 0.53% 47
2014
Q1 		$1.14M Hold
6,000
– – 0.54% 48
2013
Q4 		$1.18M Buy
+6,000
New +$1.11M 0.53% 33

Other funds holding EVGN

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Harvey Partners's EVGN Position: Q4 2014 in Review

Harvey Partners sold out of Evogene (EVGN) in Q4 2014, closing a stake of 6,000 shares — an estimated $790K sold.

Harvey Partners first reported a position in EVGN in Q4 2013 and held it in 4 quarters. The position peaked at $1.18M in Q4 2013. 15 funds tracked by Wall St. Rank hold EVGN as of Q4 2014.

  • Harvey Partners reported no remaining Evogene position as of Q4 2014 after selling out during the quarter.
  • Harvey Partners sold 6,000 Evogene shares in Q4 2014, an estimated $790K.
  • Harvey Partners first reported a position in Evogene in Q4 2013 and held it in 4 quarters.
  • Harvey Partners's Evogene position peaked at $1.18M in Q4 2013.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q4 2014.

Based on Harvey Partners's 13F filing for Q4 2014, filed 13 Feb 2015.